Cargando…
Highly sensitive quantification of pemetrexed in human plasma using UPLC‐MS/MS to support microdosing studies
Pemetrexed is an antifolate drug approved for the treatment of non‐small‐cell lung cancer and mesothelioma. Assessing pemetrexed pharmacokinetics after administration of a microdose (100 μg) may facilitate drug–drug interaction and dose individualization studies with cytotoxic drugs, without causing...
Autores principales: | van Ewijk‐Beneken Kolmer, Eleonora W. J., Teulen, Marga J. A., Boosman, Rene J., de Rouw, Nikki, Burgers, Jacobus A., ter Heine, Rob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285051/ https://www.ncbi.nlm.nih.gov/pubmed/34741344 http://dx.doi.org/10.1002/bmc.5277 |
Ejemplares similares
-
The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer
por: de Rouw, Nikki, et al.
Publicado: (2022) -
Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis
por: de Rouw, Nikki, et al.
Publicado: (2021) -
Hyperhydration with cisplatin does not influence pemetrexed exposure
por: de Rouw, Nikki, et al.
Publicado: (2021) -
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial
por: de Rouw, Nikki, et al.
Publicado: (2022) -
Pharmacokinetic and Metabolism Studies of Curculigoside C by UPLC-MS/MS and UPLC-QTOF-MS
por: Wu, Di, et al.
Publicado: (2018)